🔗 Permalink

Inventor profile of:

Ignacio ANEGON

City:

Nantes

Country:

France

Published Applications:

19

Last publication date:

2025-04-17

Top Assignees for applications by Ignacio ANEGON

The entities that hold a legal rights for patent applications filed by inventor ANEGON Ignacio:

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) 7 Paris, France
UNIVERSITÉ DE NANTES 6 Nantes, France
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) 4 Paris Cedex 13, France
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES 4 Nantes, France
UNIVERSITE DE NANTES 4 Nantes, France
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES 3 Nantes Cedex 1, France
NANTES UNIVERSITE 3 Nantes, France
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) 2 Paris, France
UNIVERSITÉDE NANTES 1 Nantes, France
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Paris, FRANCE 1 Paris, France
Institut National De La Sante Et De La Recherche Medicale (INSERM) 1 Paris, France
UNIVERSITÉ DE NANTES 1 Nantes Cedex 1, France
CENTRE HOSPITALER UNIVERSITAIRE DE NANTES 1 Nantes, France

Recent patent applications by ANEGON Ignacio

Ignacio ANEGON from Nantes, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-04-17

US20250122300A1

Chemistry; metallurgy

ANTI-HUMAN CD45RC ANTIBODIES AND USES THEREOF

#2 | 2023-05-11

US20230147657A1

Chemistry; metallurgy

CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR HUMAN CD45RC AND USES THEREOF

#3 | 2022-03-31

US20220098264A1

Chemistry; metallurgy

MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPY

#4 | 2022-02-03

US20220033500A1

Chemistry; metallurgy

Anti-human CD45RC antibodies and uses thereof

#5 | 2021-12-30

US20210401940A1

Human necessities

Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

#6 | 2021-06-03

US20210163593A1

Chemistry; metallurgy

TREATMENT OF MONOGENIC DISEASES WITH AN ANTI-CD45RC ANTIBODY

#7 | 2021-05-20

US20210147801A1

Chemistry; metallurgy

METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A POPULATION OF CD8+CD45RCLOW/- TREGS

#8 | 2020-10-01

US20200308543A1

Chemistry; metallurgy

Methods for obtaining regulatory t cells and uses thereof

#9 | 2020-01-09

US20200010519A1

Chemistry; metallurgy

NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION

#10 | 2019-08-22

US20190255077A1

Human necessities

Methods for treating heart transplant rejection

#11 | 2019-02-28

US20190060405A1

Human necessities

Pharmaceutical composition comprising IL-34 and a mTOR inhibitor

#12 | 2018-09-06

US20180251731A1

Chemistry; metallurgy

SUBPOPULATION OF CD8+CD45RCLOW TREGS AND USES THEREOF

#13 | 2018-07-05

US20180187151A1

Chemistry; metallurgy

Methods for obtaining regulatory T cells and uses thereof

#14 | 2018-04-19

US20180106779A1

Methods and kits for labeling, detection and isolation of Foxp3 regulatory T cells, isolated population of Foxp3 regulatory T cells thus obtained and uses thereof

#15 | 2018-01-18

US20180015101A1

Human necessities

COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC TOLERANCE

#16 | 2017-08-10

US20170226209A1

Chemistry; metallurgy

AN ANTI-CD45RC ANTIBODY FOR USE AS DRUG

#17 | 2017-07-20

US20170202921A1

Human necessities

Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34

#18 | 2017-06-22

US20170173125A1

Human necessities

Isolated donor MHC-derived peptide and uses thereof

#19 | 2017-01-26

US20170021001A1

Human necessities

Isolated donor MHC-derived peptide and uses thereof

InventorID:

1777790 ⎘